NCT02114333

Trial name or title	'A comparison of the immunogenicity and descriptive safety of a live attenuated herpes zoster vaccine and the GSK herpes zoster recombinant HZ/su candidate vaccine in 50 to 59 year old and 70 to 85 year old vaccine recipients'
Methods	Allocation: randomised Endpoint classification: pharmacodynamics study Intervention model: parallel assignment Masking: single‐blind (participant) Primary purpose: basic science
Participants	160 healthy volunteers aged 50 years to 85 years, both genders
Interventions	1. No previous zoster vaccine: live zoster vaccine subcutaneous and second dose placebo, normal saline subcutaneous 2. No previous zoster vaccine: recombinant vaccine HZ/su intramuscular and second dose recombinant vaccine intramuscular 3. 1 previous dose of zoster vaccine at least 5 years previously: live zoster vaccine subcutaneous and second dose placebo, normal saline subcutaneous 4. 1 previous dose of zoster vaccine at least 5 years previously: recombinant vaccine HZ/su intramuscular and second dose recombinant vaccine intramuscular
Outcomes	Unsolicited adverse events, interferon gamma/ Interleukin 2 (IFNg/IL2) dual colour fluorospot number, glycoprotein‐based enzyme‐linked immunosorbent assay (gpELISA)
Starting date	May 2014
Contact information	Please refer to this study by its ClinicalTrials.gov identifier: NCT02114333
Notes	This study is currently recruiting participants. No publications provided